These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8362982)

  • 21. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
    J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
    Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
    Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
    Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
    Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma.
    Jalkanen S; Joensuu H; Söderström KO; Klemi P
    J Clin Invest; 1991 May; 87(5):1835-40. PubMed ID: 2022749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
    Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
    Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
    Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of c-erbB2 expression in breast cancer.
    Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
    J Surg Oncol; 2002 Apr; 79(4):216-23. PubMed ID: 11920778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The relationship between expression of interleukin-8 and prognosis of breast cancer].
    Yao C; Wang SM; Xie D; Wu HX; Chen DY; Lin Y
    Zhonghua Wai Ke Za Zhi; 2006 Jul; 44(13):900-3. PubMed ID: 17067482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
    Huang J; Tan PH; Thiyagarajan J; Bay BH
    Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.
    van Diest PJ; Michalides RJ; Jannink L; van der Valk P; Peterse HL; de Jong JS; Meijer CJ; Baak JP
    Am J Pathol; 1997 Feb; 150(2):705-11. PubMed ID: 9033283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
    Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of CD59 expression in breast tumours correlates with poor survival.
    Madjd Z; Pinder SE; Paish C; Ellis IO; Carmichael J; Durrant LG
    J Pathol; 2003 Aug; 200(5):633-9. PubMed ID: 12898600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.